Case-control study of percutaneous transhepatic sclerotherapy and transcatheter arterial embolization for hepatic hemangioma

YUXiaolong; LIJianke; HUANGYouhua; XUQiang; SHENTao; SHIHongjian

Abstract：ObjectiveTo evaluate the clinical efficacy of percutaneous transhepatic sclerotherapy and transcatheter arterial embolization(TAE) for hepatic hemangioma.MethodsTwenty-two patients with hepatic hemangioma (maximum lesion diameter ≥5 cm) were randomly divided into two groups. 11 patients underwent percutaneous intrahepatic sclerotherapy with bleomycin (hardening group), and 11 patients underwent DSA guidance lower bleomycin iodized oil hepatic artery embolization (embolic group). The average operation time, cost, postoperative efficacy, complications and satisfaction of the two methods were compared.ResultsThe mean operative time of the sclerosing group was shorter than that of the embolization group (P<0.05). The proportion of abnormal liver function 3 days after embolization group In the sclerosing group was greater than that of sclerosing group (P<0.05). The average length of hospital stay and cost in the sclerosing group was significantly less than that in the embolization group (P<0.01). At 6 months after surgery, the tumors of all patients were smaller than before. The effective rates of the sclerosing group and the embolization group were 81.8%, 92.3%, with no significant difference (P>0.05).ConclusionPercutaneous liver puncture bleomycin injection sclerotherapy and DSA-guided bleomycin hepatic artery embolization have a curative effect in the treatment of hepatic hemangioma with diameter≥5 cm. Percutaneous transhepatic sclerotherapy for hepatic hemangioma has the advantages of simple operation, short operation time and hospitalization time, low treatment cost and good tolerance.